* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNA...
* Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved ...
* Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (lut...
* TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta...
* TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-l...
* Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218...
* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) sco...
* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episod...
* TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizu...
* The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. ...
- Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagon...